



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29342/36212Serial No.
09/558,9Applicant
Emmick et al.Filing Date
04/26/00Group
1646**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

RECEIVED
JUL 10 2001
TECH CENTER 1600/2600**U.S. PATENT DOCUMENTS**

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
WZ	4,931,445	06/05/90	Goldstein et al.	514	252	
	5,702,936	12/30/97	Beavo et al.	435	196	
	5,859,006	01/12/99	Daugan	514	249	
	5,981,527	11/09/99	Daugan et al.	514	250	
	5,985,326	11/16/99	Butler	424	484	
WZ	6,001,847	12/14/99	Daugan et al.	514	287	

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
WZ	WO 96/32003	10.96					
	WO 97/03675	06.02.97	PCT	A61K	31/495		
	WO 99/59584	25.11.99	PCT	A61K	31/415		
	WO 00/20033	13.04.00	PCT	A61K	41/00	x (abstract only)	
	WO 97/43287	20.11.97	PCT	C07D	471/04		
	WO 00/15639	23.03.00	PCT	C07D	471/04		
WZ	2,020,630	1991/01/08	CA	C07D	487/04	X	

EXAMINER

DATE CONSIDERED

08/01/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29342/36212Serial No.
09/558,9Applicant
Emmick et al.Filing Date
04/26/00Group
1646**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

RECEIVED
JUL 10 2001
TECH CENTER 1600/2600**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**


M/3		<i>Physicians' Desk Reference, 53 Edition, 1999, pp. 2424-2427.</i>
		Rosen et al., The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction, <i>Urology</i> , 49(6), pp. 822-830 (1997).
		K.J. Murray, Phosphodiesterase PDE V _A inhibitors, <i>DN&P</i> , 6(3), pp. 150-156 (1993).
		A. Taher et al. <i>J. Urology</i> , 149:285a, AUA Eighty-Eighth Annual Meeting, May, 1993.
		M. Boolell et al., Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, <i>Int. J. of Impotence Res.</i> , 8, pp. 47-52 (1996).
		A.M. Martel et al., Treatment of erectile dysfunction phosphodiesterase V inhibitor, <i>Drugs of the Future</i> , 22(2), pp. 138-143 (1997).
		J.N. Wells et al., Cyclic nucleotide, phosphodiesterase activities of pig coronary arteries, <i>Biochim. Biophys. Acta</i> , 384, pp. 430-442 (1975).
		A. Sitaramayya et al., On the mechanism of light activation of retinal rod outer segments cyclic GMP phosphodiesterase (light activation-influence of bleached rhodopsin and KF-deinhibition), <i>Exp. Eye Res.</i> , 25, pp. 163-169 (1977).
		N. Virmaux et al., Proteins of bovine retinal outer segments: electrophoresis on polyacrylamide gels in the presence of sodium dodecyl sulfate, <i>FEBS Letters</i> , 12(6), pp. 325-328 (1971).
		K. Loughney et al., Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases, <i>The Journal of Biological Chemistry</i> , 271(2), pp. 796-806 (1996).
M/2		Y.C. Cheng et al., Relationship between the inhibition constant (K _i) and the concentration of inhibitor which causes 50 per cent [sic] inhibition (I ₅₀) of an enzymatic reaction, <i>Biochem. Pharmacol.</i> , 22, pp. 3099-3108 (1973).

EXAMINER

DATE CONSIDERED

08/09/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29342/36212Serial No.
09/558,911Applicant
Emmick et al.Filing Date
04/26/00Group
1646

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED
JUL 10 2001
TECH CENTER 1600/2600

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MR2	D. Webb et al., Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist, <i>Amer. J. of Cardiology</i> , 83(5A), pp. 21C-28C (1999).
	V. Price et al., Expression of heterologous proteins in <i>Saccharomyces cerevisiae</i> using the ADH2 promoter, <i>Methods in Enzymology</i> , 185, pp. 308-318 (1990).
	H. Shichi et al., Biochemistry of visual pigments, <i>J. Biol. Chem.</i> , 244(3), pp. 529-536 (1969).
	Goldenberg, "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction," <i>Clinical therapeutics</i> , 20, No. 6, pp. 1033-1048 (1998).
	Israel, "Viagra: The first oral treatment for impotence," <i>The Pharmaceutical Journal</i> , 261, pp. 164-165 (1998).
	C. Conti et al., <i>Amer. J. of Cardiology</i> , 83(5A), 29C-34C (March 4, 1999).
	I. Goldstein et al., <i>The New England Journal of Medicine</i> , Vol. 338, No. 20, pp. 1397-1404 (1998).
	S.A. Ballard et al., <i>The Journal of Urology</i> , Vol. 159, pp. 2164-2171 (1998).
	Product insert, VIAGRA® Tablets (2000).
WB	Gennaro et al., Ed., Remington: The Science and Practice of Pharmacy, 19th Ed., p. 806 (1995).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.